Retrospective Claims Data and Patient Reported-Outcomes from COMMANDS Trial in Lower-Risk MDS
February 27th 2024Amy DeZern, MD, MHS, discusses a retrospective study on healthcare claims for patients with MDS treated with luspatercept and reviews patient-reported outcomes from the COMMANDS trial.
Read More
Promising Data for Pevonedistat in High-Risk MDS
Amy DeZern, MD, MHS leads a discussion surrounding the mechanism of action and clinical trial data on the use of magrolimab and pevonedistat in patients with high-risk myelodysplastic syndrome.
Read More
Emerging Role of Venetoclax in the Treatment of MDS
Rami Komrokji, MD and Gail Roboz, MD, discuss treatment considerations and clinical trial data surrounding the use of venetoclax in patients with myelodysplastic syndrome or acute myeloid leukemia.
Read More
Treatment in Older Patients with High-Risk MDS
Azra Raza, MD, discusses considerations for use of hypomethylating agents in older patients with high-risk myelodysplastic syndrome.
Read More
The panel of experts comment on the optimal timing of hypomethylating agents and transplant in patients with high-risk myelodysplastic syndrome.
Read More
Use of HMAs for the Treatment of MDS
The panel of experts highlight the risk factors and considerations for use of hypomethylating agents in patients with myelodysplastic syndrome versus acute myeloid leukemia.
Read More
Treatment of Transfusion Dependent MDS
The panel of experts reflect on the use of lenalidomide in patients with myelodysplastic syndrome who are transfusion dependent.
Read More
Luspatercept: An Erythroid Maturation Agent in MDS
Rami Komrokji, MD discusses the recent approval and FDA indication for the use of the erythroid maturation agent luspatercept.
Read More
ESA Use in the Treatment of MDS
The panel of experts discusses considerations necessary when recommending treatment with erythropoiesis-stimulating agents in patients with myelodysplastic syndrome.
Read More